Pliant Therapeutics, Inc. $PLRX

What the company doesAI summary of filing

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing product candidates, including PLN-101095, for cancer treatment. The company is evaluating PLN-101095 as both a monotherapy and in combination with pembrolizumab, a currently approved cancer therapy. The company has not yet received marketing approval for any products and generates no product revenue; its business model depends on obtaining regulatory approval and successfully commercializing its candidates. Pliant's success depends on protecting its intellectual property, navigating extensive healthcare regulations and reimbursement requirements in the United States and foreign jurisdictions, and managing compliance with laws governing drug development, manufacturing, marketing, pricing and international operations. [10-K 2026-03-11]